Skip to main content

Select Drug Profiles

Perspectives
Welcome to our community
Thomas McCarter, MD, FACP
Read More
Practice Management
Medicare Coverage Strategies: Impact of the MMA and PBMs
Stakeholder Perspective
by Joseph R. Antos, PhD
Read More
Practice Management
Disruptive Innovation: Value-Based Health Plans
F. Randy Vogenberg, PhD, FASHP
Stakeholder Perspective
Value-Based Drug Benefit: Implications for Manufacturers
by Kip Piper, MA, FACHE
Read More
Practice Management
Role of NCCN in Integrating Cancer Clinical Practice Guidelines into the Healthcare Debate
Al B. Benson III, MD, FACP, FASCO, Elizabeth Brown, MD
Stakeholder Perspective
AHDB Stakeholder Perspective
Read More
Original Research
Measuring the Value of Treatment to Patients: Patient-Reported Outcomes in Drug Development
Richard J. Willke, PhD
Stakeholder Perspective
AHDB Stakeholder Perspective
Read More
FDA Approvals
Approvable Letters in 2007 and the Outlook for 2008
Mark Senak, JD
Read More
Practice Management
The 2007 Pharmaceutical and Biotech Pipeline Year-End Summary: What it Says About the State of the Art of Discovery & Development
Michael F. Murphy, MD, PhD
Read More
Perspectives
Contracting for Compliance: Using Adherence as a Patient-Centered Measure of Performance
Scott R. Taylor, RPh, MBA, J. B. Jones, PhD, MBA, Nirav R. Shah, MD,MPH
Read More
Practice Management
Wayward Prescriptions: Costs of Fraud in Payor Plans
Thomas Kaye, RPh, MBA, FASHP
Stakeholder Perspective
Procedures Needed to Prevent Prescription Fraud
by Susan Sarnoff, DSW
Read More
Bustling Pipeline for Diabetes and Its Metabolic Consequences
Wayne Kuznar
Read More
Page 233 of 244
Results 2321 - 2330 of 2438